US2007254893A1PendingUtilityA1

Combination Product Comprising Src Kinase Inhibitor Azdo530 and an Antioestrogen or Egfr-Tk-Inhibitor

25
Individually held — no corporate assignee on recordPriority: May 29, 2004Filed: May 26, 2005Published: Nov 1, 2007
Est. expiryMay 29, 2024(expired)· nominal 20-yr term from priority
Inventors:Tim Green
A61P 43/00A61K 45/06A61K 31/4196A61K 31/5377A61K 31/517A61P 35/00A61K 31/4706A61K 31/138A61K 31/519A61K 31/566A61K 31/565
25
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a combination for use in the synergistic treatment of breast cancer comprising an antioestrogen and the Src kinase inhibitor AZD0530, a combination for the synergistic treatment of cancer comprising an EGFR TKI and the Src kinase inhibitor AZD0530 and a triple combination for the synergistic treatment of breast cancer comprising an antioestrogen, an EGFR TKI and the Src kinase inhibitor AZD0530.

Claims

exact text as granted — not AI-modified
1 . A combination suitable for use in the synergistic treatment of breast cancer comprising an antioestrogen and the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof.  
   
   
       2 . A pharmaceutical composition suitable for use in the synergistic treatment of breast cancer which comprises a combination according to  claim 1  in association with a pharmaceutically-acceptable excipient or carrier.  
   
   
       3 . A pharmaceutical composition according to  claim 2  which comprises an antioestrogen, the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable excipient or carrier.  
   
   
       4 . A pharmaceutical composition according to  claim 2  which comprises a first composition comprising an antioestrogen and a pharmaceutically-acceptable excipient or carrier, and a second composition comprising the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable excipient or carrier.  
   
   
       5 . The use of a combination according to  claim 1  in the manufacture of a medicament for administration to a warm-blooded animal to provide the synergistic treatment of breast cancer.  
   
   
       6 . The use of a combination according to  claim 1  in the manufacture of a medicament for administration to a warm-blooded animal to provide the treatment of antioestrogen-resistant breast cancer.  
   
   
       7 . A method for the synergistic treatment of breast cancer which comprises the administration to a warm-blooded animal that is in need of such treatment of effective amounts of the components of the combination according to  claim 1 .  
   
   
       8 . A method for the treatment of antioestrogen-resistant breast cancer which comprises the administration to a warm-blooded animal that is in need of such treatment of effective amounts of the components of the combination according to  claim 1 .  
   
   
       9 . A combination comprising an antioestrogen and the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, according to  claim 1  for use in the delay of the progression of breast cancer from a hormonally responsive to a hormonally non-responsive state.  
   
   
       10 . A combination comprising an antioestrogen and the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, according to  claim 1  for use in reducing the transformation of normal breast cells to a DCIS state.  
   
   
       11 . A combination comprising an antioestrogen and the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, according to  claim 1  for use in reducing the transformation of normal breast cells or DCIS cells to a malignant state.  
   
   
       12 . A combination suitable for use in the synergistic treatment of cancer comprising an EGFR TKI, or a pharmaceutically-acceptable salt thereof, and the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof.  
   
   
       13 . A pharmaceutical composition suitable for use in the synergistic treatment of cancer which comprises a combination according to  claim 12  in association with a pharmaceutically-acceptable excipient or carrier.  
   
   
       14 . A pharmaceutical composition suitable for use in the synergistic treatment of cancer according to  claim 13  which comprises an EGFR TKI, or a pharmaceutically-acceptable salt thereof, the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable excipient or carrier.  
   
   
       15 . A pharmaceutical composition according to  claim 13  which comprises a first composition comprising an EGFR TKI, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable excipient or carrier, and a second composition comprising the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable excipient or carrier.  
   
   
       16 . The use of a combination according to  claim 12  in the manufacture of a medicament for administration to a warm-blooded animal to provide the synergistic treatment of cancer.  
   
   
       17 . The use of a combination according to  claim 12  in the manufacture of a medicament for administration to a warm-blooded animal to provide the treatment of EGFR TKI resistant cancer.  
   
   
       18 . A method for the synergistic treatment of cancer which comprises the administration to a warm-blooded animal that is in need of such treatment of effective amounts of the components of the combination according to  claim 12 .  
   
   
       19 . A method for the treatment of EGFR TKI resistant cancer which comprises the administration to a warm-blooded animal that is in need of such treatment of effective amounts of the components of the combination according to  claim 12 .  
   
   
       20 . A triple combination suitable for use in the synergistic treatment of breast cancer comprising an antioestrogen, an EGFR TKI, or a pharmaceutically-acceptable salt thereof, and the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof.  
   
   
       21 . A pharmaceutical composition suitable for use in the synergistic treatment of breast cancer which comprises a triple combination according to  claim 20  in association with a pharmaceutically-acceptable excipient or carrier.  
   
   
       22 . A pharmaceutical composition suitable for use in the synergistic treatment of breast cancer which comprises a combination according to  claim 20  of an antioestrogen, an EGFR TKI, or a pharmaceutically-acceptable salt thereof, and the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable excipient or carrier.  
   
   
       23 . A pharmaceutical composition according to  claim 21  which comprises a first composition comprising an antioestrogen and a pharmaceutically-acceptable excipient or carrier, a second composition comprising an EGFR TKI, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable excipient or carrier, and a third composition comprising the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable excipient or carrier.  
   
   
       24 . The use of a triple combination according to  claim 20  in the manufacture of a medicament for administration to a warm-blooded animal to provide the synergistic treatment of breast cancer.  
   
   
       25 . The use of a triple combination according to  claim 20  in the manufacture of a medicament for administration to a warm-blooded animal to provide the treatment of antioestrogen-resistant breast cancer  
   
   
       26 . The use of a triple combination according to  claim 20  in the manufacture of a medicament for administration to a warm-blooded animal to provide the treatment of EGFR TKI resistant breast cancer.  
   
   
       27 . The use of a triple combination according to  claim 20  in the manufacture of a medicament for administration to a warm-blooded animal to provide the treatment of breast cancer that is resistant to both antioestrogen and EGFR TKI therapy.  
   
   
       28 . A method for the synergistic treatment of breast cancer which comprises the administration to a warm-blooded animal that is in need of such treatment of effective amounts of the components of the triple combination according to  claim 20 .  
   
   
       29 . A method for the treatment of antioestrogen-resistant breast cancer which comprises the administration to a warm-blooded animal that is in need of such treatment of effective amounts of the components of the triple combination according to  claim 20 .  
   
   
       30 . A method for the treatment of EGFR TKI resistant breast cancer which comprises the administration to a warm-blooded animal that is in need of such treatment of effective amounts of the components of the triple combination according to  claim 20 .  
   
   
       31 . A method for the treatment of breast cancer that is resistant to both antioestrogen and EGFR TKI therapy which comprises the administration to a warm-blooded animal that is in need of such treatment of effective amounts of the components of the triple combination according to  claim 20 .  
   
   
       32 . A triple combination according to  claim 20  comprising an antioestrogen, an EGFR TKI, or a pharmaceutically-acceptable salt thereof, and the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, for use in the delay of the progression of breast cancer from a hormonally responsive to a hormonally non-responsive state.  
   
   
       33 . A triple combination according to  claim 20  comprising an antioestrogen, an EGFR TKI, or a pharmaceutically-acceptable salt thereof, and the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, for use in reducing the transformation of normal breast cells to a DCIS state.  
   
   
       34 . A triple combination according to  claim 20  comprising an antioestrogen, an EGFR TKI, or a pharmaceutically-acceptable salt thereof, and the Src kinase inhibitor AZD0530, or a pharmaceutically-acceptable salt thereof, for use in reducing the transformation of normal breast cells or DCIS cells to a malignant state.

Join the waitlist — get patent alerts

Track US2007254893A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.